Share Print

News Archive


ipal Doubles Revenues and Reduces Costs

As a result of ten years of patent commercialization for Berlin’s universities, ipal looks back on its most successful year to date. In 2012, the revenues from the commercialization of intellectual property rights increased to €1.16 m compared to €0.5 m in 2011, which implies an increase of 135 percent. Through new agreements the company generated €1.05 m, including a patent sale for an semiconductor invention from TU Berlin, which generated €0.89 m, and a license agreement with Vattenfall concerning an absorption cooling technology from TU Berlin.


ipal granted the exclusive global using rights for a platform technology in the field of cell and gene therapy to Miltenyi Biotec. The German company based in Bergisch Gladbach is specialized in the worldwide marketing of research and development tools and the license they have been granted serves as a great complement to the company’s broad portfolio.



Germany is market leader in a variety of areas such as optical technologies, microsystems engineering, and plant manufacturing, but did not keep pace with countries like China, Scandinavia and the USA, in other fields. The initiative “Sachen machen” seeks to reinforce Germany’s role as a leading technology hub.